

**BOOK NOW TO SAVE
UP TO \$600**

February 12-13, 2019 | Boston, USA

www.immunometabolismdrugdev.com



immunometabolism **Drug Development** Summit

**Successfully Overcome Basic Biology,
Target Identification & Translational
Challenges of Immune Cell Metabolism
to Translate & Develop Clinically Safe
and Effective Therapies for Immune-
Mediated Diseases**

Expert Speakers Including:



Laurence Turka
CSO
Rheos Medicines



Robert Wild
CSO
Dracen Pharmaceuticals



Paul-Peter Tak
Professor of Medicine,
Amsterdam University Medical
Center; Director
**Levixcept & Sitryx
Therapeutics**



**Martin-Alexander
Schneider**
Senior Investigator I
**Novartis Institutes of
BioMedical Research
(NIBR)**



Lauriane Cabon
Scientist, Investigative
Safety, Roche Pharma
Research & Early
Development
Roche



Mateusz Nowak
Head of Cancer Metabolism
& Immunometabolism
Platform
Selvita

Immunometabolism Drug Development Summit 2019

As scientific breakthroughs and novel discoveries reveal the causal link and interface between metabolic pathways and immune cell function, the inaugural Immunometabolism Drug Development Summit 2019 is dedicated to help large pharma, biotech and academia translate basic immunometabolism research into a novel class of clinically safe and effective therapeutics for immune-mediated diseases.

The field of immunometabolism has thrived over the last decade, revealing not only a better understanding of immune cells and their functions but also the impact of key metabolic pathways on immune cell development, fate, and behavior. As such the emerging field of immunometabolism offers a tremendous opportunity to set a higher standard for how immune-mediated diseases are treated.

Built with key insight from large pharma, biotech and KOLs from academia, this summit is specifically focused on optimizing and accelerating the discovery, translational research and ultimately clinical development of immunometabolism based drugs across all therapeutic indications, in particular autoimmunity and oncology.

Why our speakers are looking forward to this summit?

“This summit would be a great opportunity to meet experts and discuss the most recent advances in the exciting immunometabolism field from both a mechanistic and therapeutic perspective”

Madhusudhanan Sukumar,
Staff Scientist, National Cancer Institute/National Institutes of Health



What Can You Expect?



60+
ATTENDEES



6+
HOURS OF DEDICATED
NETWORKING



14+
REAL WORLD
CASE STUDIES



1
INTERACTIVE
WORKSHOP

Why Attend the 1st Immunometabolism Drug Development Summit 2019?

1.

Address knowledge gap and benchmark against the basic biology of immunometabolism to enhance or temper immunity with insights from **Novartis Institutes of BioMedical Research (NIBR), Dracen Pharmaceuticals & ImmunoMet Therapeutics**




2.

Overcome challenges associated with identification & validation of novel metabolic targets with insights from **Rheos Medicines, Selvita & Roche**



3.

Widen your expertise & knowledge on the path forward from pre-clinical to translational studies for robust immunometabolism drug development with insights from **Max Planck Institute of Immunobiology, Vanderbilt University Medical Center & Roche**



4.

Learn more about the challenges and opportunities to translate immunometabolism therapies into clinic safely & effectively with insights from **Duke University Medical Center, Tempest Therapeutics, Rheos Medicines & Landos Biopharma**



5.

Join pioneers of the field of immunometabolism and discuss the most recent advances in this exciting field from both a mechanistic and therapeutic perspective with insights from **Duke Cancer Institute, National Cancer Institute/National Institutes of Health & University of Florida**



Your Expert Speakers



Thomas W. Dubensky
CEO
Tempest Therapeutics



Josep Bassaganya-Riera
Chairman & CEO
Landos Biopharma



Arpita Maiti
Senior Director,
External Science
& Innovation,
Inflammation,
Immunology and
Microbiome
Pfizer



E. William St.Clair
W. Lester Brooks,
Jr. Professor of
Medicine
**Duke University
Medical Center**



Jeffrey Rathmell
Professor of
Immunobiology
**Vanderbilt
University Medical
Center**



Sanghee Yoo
VP Head of Biology
**ImmunoMet
Therapeutics**



Edward Pearce
Senior Group Leader;
Professor of Biology
**Max Planck Institute
of Immunobiology &
Epigenetics,
University of
Freiburg**



**Martin-Alexander
Schneider**
Senior Investigator I
**Novartis Institutes
of BioMedical
Research (NIBR)**



**Hozefa
Bandukwala**
Senior Director,
Head of Discovery
Biology
Rheos Medicines



Brent Hanks
Assistant Professor,
Department of
Medicine; Department
of Pharmacology &
Cancer Biology
**Duke University, Duke
Cancer Institute**



Robert Wild
CSO
**Dracen
Pharmaceuticals**



Laurence Turka
CSO
Rheos Medicines



Mateusz Nowak
Head of Cancer
Metabolism &
Immunometabolism
Platform
Selvita



Paul-Peter Tak
Professor of Medicine,
Amsterdam University
Medical Center;
Director
**Levcept & Sitryx
Therapeutics**



Lauriane Cabon
Scientist,
Investigative Safety,
Roche Pharma
Research & Early
Development
Roche



Laurence Morel
Mary and Bryan
Whisenant Professor
of Pathology; Vice
Chair for Research
& Academic Affairs,
Department of
Pathology, Immunology,
& Laboratory Medicine
University of Florida



**Madhusudhanan
Sukumar**
Staff Scientist
**National Cancer
Institute/National
Institutes of Health**



Leandro Agudelo
Postdoctoral
Associate
**Massachusetts
Institute of
Technology,
Computer Science
and Artificial
Intelligence
Laboratory**

Why Are Our Expert Speakers Getting Involved at the Summit?

“I am enthusiastic about exchanging ideas on immunometabolism in the context of drug development. I expect the summit to foster collaborations and to challenge what needs to be addressed in the future to pave the way for therapeutics which can benefit patients”



Lauriane Cabon
Roche

“I am excited to join conversations focused on translating immunometabolism towards novel therapies for patients with immune-mediated diseases”



Hozefa Bandukwala
Rheos Medicines

“It is exciting to have this conference going beyond academic understanding of immune metabolism, and discussing immune metabolism as a potential way to treat disease and sharing challenges and solutions during the process”



Sanghee Yoo
ImmunoMet Therapeutics

“This summit creates an opportunity to share my excitement about a bold new approach for tuning immune cells in disease settings”



E. William St.Clair
Duke University
Medical Center

“I look forward to learning from my peers on immunometabolism approaches and strategies as well as how to address current challenges in developing agents in this space”



Robert Wild
Dracen
Pharmaceuticals

Conference Day One | Tuesday, 12 February, 2019

8.00 Registration & Breakfast

9.00 Chair's Opening Remarks

Arpita Maiti

Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome

Pfizer

Addressing Knowledge Gap: Manipulating Cellular Metabolism in Different Immune Cells to Enhance or Temper Immunity

Jeffrey Rathmell
 Professor of Immunobiology
Vanderbilt University Medical Center

9.10 Fueling T Cell Activation and Differentiation

- Glutamine is metabolized differently by distinct T cell subsets
- Metabolic influence on epigenetic marks promotes specific T cell populations
- Targeting glutamine can selectively impact T cell-dependent inflammation

Martin-Alexander Schneider
 Senior Investigator I
Novartis Institutes of BioMedical Research (NIBR)

9.40 Exploiting T Cell Metabolism to Control Immune Cell Function and Fate

- Metabolic reprogramming of naive T cells as a fundamental part of T cell activation and expansion
- Activated T cells need to actively reprogram once more their intracellular metabolism during the contraction phase to enter into efficient memory
- These active metabolic processes are necessary for T cells to return to a quiescent but epigenetically highly modified memory state
- New and distinct opportunities for therapeutic intervention in anti-viral responses, autoimmune diseases and cancer immunotherapy through metabolic wiring in both CD4 and CD8 T cell subsets

Brent Hanks
 Assistant Professor,
 Department of Medicine;
 Department of Pharmacology & Cancer Biology
Duke University, Duke Cancer Institute

10.10 Reversing Tumor-mediated Metabolic Re-programming of Dendritic Cells as a Strategy to Augment Anti- PD-1 Checkpoint Inhibitor Immunotherapy

- Fatty acid oxidation represents a key switch for the induction of dendritic cell tolerization
- Dendritic cell fatty acid oxidation regulates indoleamine 2,3-dioxygenase enzymatic activity and pro-inflammatory cytokine expression
- Paracrine Wnt- β -catenin signalling is a key mediator of DC tolerization that contributes to anti-PD-1 resistance



10.40 Speed Networking & Morning Refreshments

Robert Wild
 CSO
Dracen Pharmaceuticals

11.40 Targeting Glutamine Metabolism for the Treatment of Cancer: An Art, a Science or Both?

- Many cancers are glutamine addicted and blocking tumor glutamine metabolism results in potent single agent anti-tumor activity
- Glutamine antagonism remodels the tumor microenvironment resulting in potent stimulation of an adaptive anti-tumor immune response
- Induction of immune responses results in potent synergy with existing immune-oncology therapies, including checkpoint inhibitors

Sanghee Yoo
 VP Head of Biology
ImmunoMet Therapeutics

12.10 Central Role of Mitochondria in Immune Cell Metabolism and Targeting Mitochondria as a Potential Therapy for Immune Disorders

- Immune cells adopt different metabolic strategy depending on their function and status
- Mitochondria generates key biological molecules such as ATP, NAD⁺, ROS and TCA cycle intermediates and plays pivotal roles in cellular metabolism by the regulation of signalling and gene expression
- The complex I inhibition in OXPHOS leads to significant impacts on OXPHOS dependent immune cells and is a potential approach to rebalance immune cells in immune disorders

 Madhusudhanan Sukumar Staff Scientist National Cancer Institute/National Institutes of Health	12.40 Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy • Metabolic competition of immune cells at the tumor microenvironment • Elevated T cell metabolic activity is necessary at the tumor site to promote tumor killing • Metabolic reprogramming of T cells may improve TCR and chimeric antigen receptor (CAR) based immunotherapy
	13.10 Networking Lunch
Identification & Validation of Novel Metabolic Targets & Strategize to Industrialize Immunometabolism Drug Discovery	
 Hozefa Bandukwala Senior Director, Head of Discovery Biology Rheos Medicines	14.10 Operationalizing Novel Target Discovery for Therapeutic Modulation of Immune Cell Metabolism • Identification of immunometabolism targets that provide an acceptable therapeutic index for efficacy with low toxicity remains a challenge • A combination of functional genomic and pharmacogenomic approaches are required for efficient target discovery • Incorporating an end-to-end strategy, including development of in vivo models, efficiently validate targets and dramatically accelerate efficient target discovery
 Mateusz Nowak Head of Cancer Metabolism & Immunometabolism Platform Selvita	14.40 Novel Dual A2A/A2B Adenosine Receptor Antagonists for Cancer Immunotherapy • Adenosine is regarded as a key immunosuppressive factor in tumor microenvironment. Adenosine induced immune evasion may be prevented by A2A/B antagonists which are active in tumor relevant high adenosine conditions • Dual mode of action of A2A/B antagonists should allow for influencing more subpopulations of immune cells infiltrating tumor than selective A2A antagonists • A2A/B antagonists discovered in Selvita are approaching preclinical development
 Lauriane Cabon Scientist, Investigative Safety, Roche Pharma Research & Early Development Roche	15.10 Targeting Mitochondrial Respiration to Control Immune Cell Functions: How to Best Exploit it Therapeutically • The interesting fundamental biology of respiratory complex I in immunology and haematology • The example of metformin and how to reinvent it in the context of immunometabolism • The identification of targets related to mitochondrial OXPHOS and their application in immuno-oncology and autoimmunity
	15.40 Afternoon Refreshments

16.10 Roundtable Discussions:

Our breakout roundtables will allow you to have more intimate discussions with thought leaders of the field of immunometabolism around some of the hottest topics in the field. Discover multiple perspectives on these key issues, so that you can learn from your fellow experts in the audience. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

1 What are the technical research issues of the field of immunometabolism?

Moderator


Sanghee Yoo
 VP Head of Biology
ImmunoMet Therapeutics

2 Which immunometabolism disease targets are "low hanging fruit"?

Moderator


Laurence Morel
 Mary and Bryan Whisenant Professor of Pathology; Vice Chair for Research & Academic Affairs, Department of Pathology, Immunology, & Laboratory Medicine
University of Florida

3 Routes for translational success from discovery to clinic: What will be the key factors for generating successful clinical results?

Moderator


Arpita Maiti
 Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

17.00 Chair's Closing Remarks & End of Day One

Conference Day Two | Wednesday, 13 February, 2019

8.30 Breakfast & Networking

8.55 Chair's Opening Remarks


Arpita Maiti

Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

From Pre-clinical to Translation: Mapping the Path Forward for Immunometabolism Drug Development


Edward Pearce

Senior Group Leader;
 Professor of Biology
**Max Planck
 Institute of
 Immunobiology &
 Epigenetics,
 University of
 Freiburg**

9.00 Pre-clinical Studies in Immunometabolism

- Changing metabolic requirements during immune cell lifecycles create vulnerabilities that can be targeted change cellular function and fate
- New integrative approaches are capable of revealing new metabolic targets in immune cells
- Immunometabolism can leverage extensive existing knowledge of metabolism


Laurence Morel

Mary and Bryan Whisenant Professor of Pathology; Vice Chair for Research & Academic Affairs, Department of Pathology, Immunology, & Laboratory Medicine
University of Florida

9.30 Immunometabolism Checkpoints in Systemic Lupus Erythematosus

- Metabolic alterations of lupus CD4+ T cells predict their pathogenicity
- Blocking glycolysis preferentially targets autoreactive CD4+ T cells without impairing protective immunity
- Need for a systematic screen of the metabolic requirements of the major immune cell types involved in lupus, and their relevance to in vivo treatments, with and without standard-of-care treatments

10.00 Panel Discussion: Improving the Validity of *In Vitro* and *In Vivo* Studies for Immunometabolism Drug Development

- How to overcome target selectivity and distribution challenges to maximize specificity and efficacy and to minimize toxicity?
- How to interpret and apply in vivo findings for the demonstration of quality, safety and efficacy?
- Delivering on the hype and investment thus far – how to translate promising science, current investment and clear opportunity into safe and effective immunometabolism therapeutic products?

Panel Moderator


Edward Pearce

Senior Group Leader;
 Professor of Biology
**Max Planck Institute
 of Immunobiology &
 Epigenetics,
 University of Freiburg**

Panelists


Paul-Peter Tak

Professor of Medicine,
 Amsterdam University Medical Center; Director
**Levcept & Sitryx
 Therapeutics**


Lauriane Cabon

Scientist,
 Investigative Safety,
 Roche Pharma
 Research & Early
 Development
Roche


Jeffrey Rathmell

Professor of Immunobiology
**Vanderbilt
 University
 Medical Center**



10.30 Morning Refreshments & Networking

Overcoming Translational Challenges of Immunometabolism Based Therapies into the Clinic


E. William St.Clair

W. Lester Brooks, Jr.
 Professor of Medicine
**Duke University
 Medical Center**

11.15 Targeting Metabolic Pathways in Autoimmune Disease: Translating into the Clinic

- Drugs targeting metabolism are effective for the treatment of autoimmune disease and in the clinic now
- Tackling the challenges and recognizing the opportunities of drug development in autoimmune disease.
- Clinical trials of targeted therapies should be rationally designed based on molecular mechanisms linking target and disease

 Thomas W. Dubensky CEO Tempest Therapeutics	11.45 TPST-1120: A First-in-Class PPARα Antagonist that Suppresses Tumor Growth and Stimulates Anti-Tumor Immunity - Diverse malignancies and immune suppressive immune cell populations are dependent upon fatty acid oxidation (FAO) - TPST-1120 is a first-in-class orally available small molecule that inhibits FAO through antagonizing the PPARα receptor - TPST-1120 will be evaluated in the clinics in 2019 based on observations of inducing significant anti-tumor immunity in pre-clinical models and potentiating the effector function of cultured human immune cells
 Josep Bassaganya-Riera Chairman & CEO Landos Biopharma	12.15 Immunometabolic Actions of BT-11 in IBD - Immunometabolic actions of BT-11 are required for its therapeutic efficacy in IBD - LANCL2 is a novel immunometabolic target - BT-11 is a clinical-stage orally active gut-restricted immunometabolic drug
12.45 Panel Discussion: Early Clinical Design Considerations for Development of First-in-Class Immunometabolism Drugs - Getting ready for clinical trials: Early design considerations for immunometabolism therapies - Strategies for patient selection: How to subset in complex diseases? - Navigating the confounding impact of previous or clinically essential concurrent therapies Panel Moderator  Paul-Peter Tak Professor of Medicine, Amsterdam University Medical Center; Director Levcept & Sitryx Therapeutics Panelists  Laurence Turka CSO Rheos Medicines  Josep Bassaganya-Riera Chairman & CEO Landos Biopharma  Thomas W. Dubensky CEO Tempest Therapeutics	
	13.15 Chair's Closing Remarks & End of the Summit Followed by Networking Lunch

 I look forward to a lot of networking opportunities and cutting edge science from leaders in the emerging field of immunometabolism 

Mateusz Nowak, Head of Cancer Metabolism & Immunometabolism Platform, **Selvita**

Post-Conference Workshop

Wednesday, 13 February, 2019

Workshop

Multi-omics Machine and Deep Learning Inference of Metabolic States Across Immune Populations

14:15pm - 16:30pm

The pharma industry is investing in AI & machine learning technologies as the drug discovery paradigm shifts towards safe, effective and value based drug discovery. This exciting workshop will delve into the implementation of machine and deep learning models in systems immunology, focusing on how to leverage metabolic and phenotypic insights from high-dimensional data.

- Hear about and discuss the application of machine and deep learning algorithms for pattern discovery in biological data, followed by experimental validation
- Expand your knowledge on learning unsupervised representations from immune profiles
- Hear about deep learning integration of high-dimensional data: metabolism and immune-signalling
- Hear about multi-omics network inference of molecular components across immune populations
- Hear about and discuss machine teaching: the future of data integration in biology

Workshop Leader:



Leandro Agudelo
Postdoctoral Associate
Massachusetts Institute of Technology, Computer Science and Artificial Intelligence Laboratory

■ I am intrigued by the deeply intertwined relationship between metabolic re-programming of T cells and their effector function and epigenetically imprinted cell fate. This metabolic-epigenetic axis offers several opportunities for therapeutic interventions in different immunology-related settings from autoimmune disease to cancer immunotherapy ■■

Martin-Alexander Schneider, Senior Investigator I, **Novartis Institutes of BioMedical Research (NIBR)**

BECOME A COMMERCIAL PARTNER


60+
 ATTENDEES

6+
 HOURS OF DEDICATED
 NETWORKING

14+
 REAL WORLD
 CASE STUDIES

1
 INTERACTIVE
 WORKSHOP

WHY ATTEND IMMUNOMETABOLISM DRUG DEVELOPMENT SUMMIT 2019?

This summit is first of its kind as it is uniting senior experts from large pharma, innovative biotechs and leading academic institutes to discuss the translational challenges and opportunities of the young and emerging field of immunometabolism in order to move beyond the exciting basic biology and towards clinically safe and effective therapies for immune-mediated diseases.

Join your peers at this summit to get updated on the latest and novel discoveries of the field of immunometabolism, the latest investments, collaborations and the path forward for immunometabolism drug development from the senior management of the leading companies and research institutes of the space.

PARTNERSHIP OPPORTUNITIES



BENEFIT FROM MARKET INTELLIGENCE

The field of immunometabolism opens opportunity to modulate key cellular pathways with broad therapeutic applications across variety of immune-mediated diseases with unmet medical need. Hear how and where pharmaceutical giants are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly.



RAISE BRAND AWARENESS

Benefit from pre and post conference exposure to our immunometabolism KOL community and increase market share through unique branding formats. Also, differentiate your discovery, pre-clinical and translational services from other solution providers.



POSITION YOURSELF AS AN INDUSTRY EXPERT

With the emergence of biotech companies focused on immunometabolism drug development, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent expertise in front of the key decision makers in the field.



MEET AND NETWORK WITH INDUSTRY PIONEERS


With a room full of drug developers looking to see how they can effectively translate basic biology into safe and effective immunometabolism therapies, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.




GENERATE COMMERCIAL COLLABORATIONS

Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event.

SENIORITY



COMPANY BY TYPE



*Based on market research and previous events' statistics

BECOME A PARTNER



Bashir Langhi
 Partnerships Manager
T: +44(0)2031418797
E: bashir.Langhi@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK



www.immunometabolismdrugdev.com/register



Tel: +1 617 455 4188



Email: register@hansonwade.com

1

Discuss and learn more about novel immunometabolism targets as a new therapeutic approach to reprogram immune cells for oncology and autoimmune disease

2

Overcome pre-clinical and translational challenges of immunometabolism drug development for a successful translation into clinic

3

Define future scientific and strategic trends to ensure immunometabolism delivers clinically safe and effective results

Team Discounts*

• 10% discount – 3 delegates

• 15% discount – 4 delegates or more

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Industry Pricing	Register & Pay before 9 November 2018 (Save \$600!)	Standard Prices
Drug Developer & Solution Provider Pricing - Conference Only	\$1,399	\$1,999
Academic, Not-for-Profit & Start-up Pricing - Conference Only*	\$899	\$1,499
Workshop	\$399	

*T&Cs Apply: Start-up rate is subject to organizer approval. Please visit the event website for more details.

VENUE

The Colonnade Hotel
120 Huntington Avenue, Boston,
MA 02116, (617) 424-7000
Phone +1 800 962 3030

For further information or assistance please visit:
www.colonnadehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8149